LSP HEF

LSP HEF invests in companies that have products or technologies that not only improve the quality of healthcare, but reduce its cost at the same time

LSP HEF (the LSP Health Economics Fund) was launched in 2012. At its start, it received a €50 million cornerstone investment from Achmea, the largest healthcare insurance company in The Netherlands. In later closings of the fund, health insurer Menzis invested in LSP HEF followed by a number of other insurance companies, large family offices and other (semi-) institutional investors, resulting in a final fund size of €112 million. The fund’s strategy is to invest in late-stage private healthcare companies that have products on the market or are very close to market introduction. 
 
LSP HEF focuses exclusively on investments in healthcare companies that develop medical devices, diagnostics, and IT solutions for healthcare related problems. Contrary to our other funds, LSP HEF does not invest in companies that develop drugs. Crucially, the fund only invests in those companies that improve the quality of healthcare, while reducing its cost at the same time. This is generally referred to as companies with a strong “health economics case” and such companies are, for that reason, of high interest to patients, care providers and to society at large. 
 
A prime example of an actual investment of LSP HEF is IlluminOss.This company has developed a radically new approach to the treatment of bone fractures. The approach allows for an overall cost saving of 25% per patient and, in contrast to the standard of care, is minimally invasive. It leaves only a small scar, does not require a cast, reduces complications significantly and limits hospital stays. Clearly, the IlluminOss technology offers huge advantages to patients and improves the cost-efficiency of the healthcare system at the same time
 
People who have questions about LSP HEF and would like to receive more information, are kindly asked to email Rudy Dekeyser at eqrxrlfre@yfcip.pbz; alternatively, please contact one of our offices via +31 (20) 664 55 00 (Amsterdam), +49 (0) 89 330 666 0 (Munich) or +1 (781) 472-2740 (Boston) and we will ensure you are connected with Rudy Dekeyser or one of his colleagues.


LSP HEF

LSP HEF invests in companies that have products or technologies that not only improve the quality of healthcare, but reduce its cost at the same time

LSP HEF (the LSP Health Economics Fund) was launched in 2012. At its start, it received a €50 million cornerstone investment from Achmea, the largest healthcare insurance company in The Netherlands. In later closings of the fund, health insurer Menzis invested in LSP HEF followed by a number of other insurance companies, large family offices and other (semi-) institutional investors, resulting in a final fund size of €112 million. The fund’s strategy is to invest in late-stage private healthcare companies that have products on the market or are very close to market introduction. 
 
LSP HEF focuses exclusively on investments in healthcare companies that develop medical devices, diagnostics, and IT solutions for healthcare related problems. Contrary to our other funds, LSP HEF does not invest in companies that develop drugs. Crucially, the fund only invests in those companies that improve the quality of healthcare, while reducing its cost at the same time. This is generally referred to as companies with a strong “health economics case” and such companies are, for that reason, of high interest to patients, care providers and to society at large. 
 
A prime example of an actual investment of LSP HEF is IlluminOss.This company has developed a radically new approach to the treatment of bone fractures. The approach allows for an overall cost saving of 25% per patient and, in contrast to the standard of care, is minimally invasive. It leaves only a small scar, does not require a cast, reduces complications significantly and limits hospital stays. Clearly, the IlluminOss technology offers huge advantages to patients and improves the cost-efficiency of the healthcare system at the same time
 
People who have questions about LSP HEF and would like to receive more information, are kindly asked to email Rudy Dekeyser at eqrxrlfre@yfcip.pbz; alternatively, please contact one of our offices via +31 (20) 664 55 00 (Amsterdam), +49 (0) 89 330 666 0 (Munich) or +1 (781) 472-2740 (Boston) and we will ensure you are connected with Rudy Dekeyser or one of his colleagues.